In the management of a patient with a deep venous thrombosis (DVT), which direct oral anticoagulant (DOAC) can be used without injectable therapy?

Rivaroxaban is the appropriate choice in this scenario because it is a direct oral anticoagulant (DOAC) that can be initiated without the need for initial injectable anticoagulant therapy. For the treatment of DVT, rivaroxaban allows for immediate anticoagulation, which simplifies the management of the patient by eliminating the need for bridging therapy with injections such as low molecular weight heparin.

Rivaroxaban is typically administered orally, and at the initiation of treatment, the dosing is designed to achieve therapeutic anticoagulation quickly, making it a convenient option. This characteristic can significantly enhance patient compliance, as patients can begin therapy without the discomfort and inconvenience associated with injections.

Other DOACs like apixaban, edoxaban, and dabigatran usually require initial treatment with a parenteral anticoagulant for a certain period before transitioning to oral therapy. This necessitates additional steps in management, potentially complicating the treatment regimen and leading to patient non-adherence or logistical challenges. Thus, rivaroxaban stands out as it allows for direct initiation without injectable therapy, which is advantageous in the management of DVT.